Retatrutide represents a monumental leap forward in pharmacological weight management by simultaneously targeting three distinct metabolic receptors. Unlike older medications that focus on single or dual pathways, this novel peptide stimulates GLP-1, GIP, and glucagon receptors concurrently. Clinical trials demonstrate unprecedented reductions in body weight, sparking immense interest among medical…